GeoVax Labs, Inc. has reported its financial results for the second quarter of 2026, revealing a significant decline in revenue and a continued net loss. The company reported no revenue for the three and six months ended June 30, 2026, compared to $852,282 and $2,489,145 for the same periods in 2025. This drop in revenue is attributed to the termination of a government contract with the Biomedical Advanced Research and Development Authority (BARDA) in April 2025, which had previously supported the advancement of its GEO-CM04S1 vaccine candidate.
Operating expenses for GeoVax decreased during the second quarter, with total operating expenses of $4,442,072 for the three months ended June 30, 2026, down from $6,271,188 in the same period of 2025. For the six-month period, operating expenses were $9,714,953, compared to $13,313,221 in 2025. The reduction in expenses is primarily due to lower research and development costs associated with the discontinued BARDA contract and decreased general and administrative expenses. The net loss for the second quarter was $4,426,578, a decrease from the $5,369,783 loss reported in the same quarter of the previous year.
In terms of strategic developments, GeoVax is focusing on its lead programs, particularly the GEO-MVA vaccine candidate for mpox and smallpox, which is set to enter a pivotal Phase 3 clinical trial in late 2026. The company has also completed a Phase 1/2 clinical trial for its Gedeptin® therapy for advanced head and neck cancers and plans to initiate a Phase 2 trial in 2027. Additionally, GeoVax has made organizational changes, including the discontinuation of its GEO-CM04S1 COVID-19 vaccine candidate, reflecting a strategic shift towards programs with clearer regulatory pathways and market demand.
As of June 30, 2026, GeoVax reported total assets of $4,642,757, a decrease from $6,341,868 at the end of 2025. The company's cash and cash equivalents increased slightly to $3,143,422 from $3,085,741 at the end of the previous year. However, the company faces substantial doubt about its ability to continue as a going concern, as it will require additional funding to support ongoing operations and development activities. GeoVax plans to pursue various funding sources, including public or private equity, government grants, and strategic partnerships, to ensure its financial stability moving forward.
About GeoVax Labs, Inc.
GeoVax Labs, Inc. is a biotechnology company developing vaccines and immunotherapies for infectious diseases and cancers. Its portfolio includes COVID-19 vaccines, oncolytic cancer therapies, and vaccines for Mpox, smallpox, Ebola, Zika, malaria, and hemorrhagic fevers. Utilizing proprietary MVA virus-like particle platforms, GeoVax focuses on safe, durable, and broad immune responses for global health and biodefense markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov